Zydus France Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Zydus France Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Zydus France — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Zydus France

Pharmaceutical Importer · France · Antiviral & HIV Medications Focus · $1.1M Total Trade · DGFT Verified

Zydus France is a pharmaceutical importer based in France with a total trade value of $1.1M across 2 products in 1 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Zydus France sources from 4 verified Indian suppliers, with Macleods Pharmaceuticals Limited accounting for 68.6% of imports.

Zydus France — Import Portfolio & Supplier Network

Zydus France import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Zydus France?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$650.0K	14	68.6%
Zydus Lifesciences Limited	$196.9K	6	20.8%
Unison Pharmaceuticals Private Limited

What Formulations Does Zydus France Import?

Formulation	Value	Ships
Drugs and pharmaceuticals harmlessmedicines emtricitabine and tenofovir disoproxil film coated tablets	$300.0K	6
Drugs and pharmaceuticals harmlessmedicines emtricitabine and tenofovir disoproxil film coated tablets	$200.0K	4
Tramadol teva er tabs 100 MG tablets (tramadol hydrochloride) (export authorization no. : p-exp-11236/2024 date -	$107.6K	3
Medicines. emtricitabine 200MG +	$50.0K	1
Drugs and pharmaceuticals harmless medicines emtricitabine and tenofovir disoproxil film coated tablets 200 MG/ 245 MG	$50.0K	1
Drugs and pharmaceuticals harmless medicines emtricitabine and tenofovir disoproxil film coated tablets (200 MG/ 245 MG)	$50.0K	1
Tramadol teva 150MG sr tablets (tramadolextended release tablets 150MG) [3x10 per	$48.2K	1
Tramadol evolugen l.p 100MG tablets	$39.4K	1
Tramadol er 200MG tablets tramadol hcl200mg tablets [3x10t per	$34.7K	1
Bilastine zydus 20MG comprime(3x10t)bl (bilastine) (1nos=1packs)( b.no. 2430293as per inv)	$22.3K	1
Bilastine zydus 20MG comprime(3x10t)bl (bilastine)(1nos=1packs)( b.no. 2430292bas per inv)	$21.9K	1
Bilastine zydus 20MG comprime (bilastine) [21030 Pack x 3x10's] (b.no.2431170b mfg.dt. 11/24, exp.dt. 10/28)	$20.0K	1
Tramadol tablets 150MG (tramadol extended release tablets 150MG) [1x10 per	$1.6K	1
Bilastine zydus 20MG comprime (bilastine) [1892 Pack x 1x10's] (b.no.2431170a mfg.dt. 11/24, exp.dt. 10/28)	$929	1
Bilastine zydus 20MG comprime(1x10t)bl(bilastine)(1nos=1packs)( b.no. 2430292a as per inv)	$570	1

Zydus France imports 16 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Emtricitabine	Antiviral & HIV Medications	$600.0K	12	0.5%	4
2	Tenofovir	Antiviral & HIV Medications	$500.0K	10	0.0%	15

Zydus France imports 2 pharmaceutical products across 1 categories into France totaling $1.1M.

Zydus France — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Zydus France is a pharmaceutical importer and distributor based in Nanterre, Île-de-France, operating as a 100% subsidiary of Zydus International Private Limited, Ireland, which is ultimately owned by Cadila Healthcare Limited, headquartered in Ahmedabad, India. Established in 2003, Zydus France focuses on the importation and distribution of generic pharmaceutical products within the French market. The company offers a diverse portfolio, including tablets, ointments, and syrups, catering to various therapeutic areas.

As part of the Zydus Lifesciences Limited group, Zydus France benefits from the parent company's extensive global presence and manufacturing capabilities. Zydus Lifesciences ranks fourth in the Indian pharmaceutical industry and has a strong presence in regulated markets such as the US and Europe, including France and Spain. This affiliation enables Zydus France to leverage the group's research and development resources, ensuring access to a broad range of high-quality generic medications.

2Distribution Network

Zydus France operates its distribution network from its headquarters in Nanterre, Île-de-France. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in the Paris metropolitan area suggests efficient access to major transportation hubs, facilitating nationwide distribution. The French pharmaceutical market is well-developed, with a robust infrastructure supporting the distribution of pharmaceutical products across the country. Zydus France's affiliation with Zydus Lifesciences Limited, which has manufacturing sites and research facilities in India, the US, and Brazil, likely supports its import operations, ensuring a steady supply of products to meet market demand.

3Industry Role

In the French pharmaceutical supply chain, Zydus France functions primarily as a pharmaceutical importer and distributor, focusing on generic medications. The company imports finished pharmaceutical formulations from India and other markets, ensuring compliance with French regulatory standards. By offering a range of generic products, Zydus France contributes to enhancing the accessibility and affordability of healthcare in France, aligning with the country's emphasis on promoting generic drug use to manage healthcare costs. The company's role is crucial in bridging the gap between international manufacturers and the French healthcare system, ensuring a consistent supply of quality generic medications to meet patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Zydus France

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Zydus France's sourcing strategy exhibits a notable concentration, with a significant portion of its imports originating from a single supplier, MACLEODS PHARMACEUTICALS LIMITED. This supplier accounts for approximately 68.6% of the total import value, amounting to $650,000 across 14 shipments. The remaining imports are distributed among three other suppliers: ZYDUS LIFESCIENCES LIMITED (20.8%), UNISON PHARMACEUTICALS PRIVATE LIMITED (6.9%), and CADILA HEALTHCARE LIMITED (3.7%). This concentration indicates a strategic choice to maintain strong partnerships with key suppliers, potentially ensuring favorable terms and consistent product quality.

However, such dependency on a single supplier can pose risks, including supply chain disruptions due to unforeseen events affecting that supplier. The limited number of suppliers also suggests a lack of diversification, which could impact Zydus France's ability to adapt to market changes or shifts in supplier capabilities. To mitigate these risks, it would be prudent for Zydus France to consider diversifying its supplier base, thereby enhancing supply chain resilience and reducing potential vulnerabilities.

2Supply Chain Resilience

Zydus France's supply chain resilience is closely tied to its sourcing strategy. The heavy reliance on MACLEODS PHARMACEUTICALS LIMITED for the majority of imports indicates a concentrated supply chain, which may be susceptible to disruptions. The limited number of suppliers—four in total—suggests a lack of diversification, potentially affecting the company's ability to adapt to changes in the market or supply chain dynamics.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of health products available in the French market. Key legislation governing pharmaceutical imports includes the Public Health Code (Code de la santé publique), which outlines the requirements for marketing authorization, importation, and distribution of pharmaceutical products.

For Indian generics to be marketed in France, they must obtain a marketing authorization from ANSM. This process involves submitting a comprehensive dossier demonstrating the product's quality, safety, and efficacy. The dossier must include detailed information on the manufacturing process, quality control measures, and clinical data supporting the product's therapeutic indications. Once approved, the product is granted a marketing authorization number, allowing it to be legally marketed and distributed within France.

2Import Licensing & GMP

Import licensing requirements in France stipulate that pharmaceutical products must be accompanied by a valid marketing authorization issued by ANSM. Additionally, importers must ensure that their suppliers comply with recognized Good Manufacturing Practices (GMP), such as EU GMP, WHO GMP, or PIC/S standards. This compliance ensures that imported products meet the necessary quality standards and are safe for patient use.

Zydus France — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Zydus France's focus on importing antiviral and HIV medications aligns with the therapeutic needs of the French population, addressing prevalent health concerns and contributing to public health objectives. The market demand for these products is driven by the ongoing need for effective treatments for HIV and related conditions, as well as the French healthcare system's commitment to providing comprehensive care for individuals living with HIV.

By concentrating on these therapeutic areas, Zydus France positions itself as a key player in the French pharmaceutical market, offering essential medications that support the health and well-being of the population. This strategic focus also allows the company to leverage its expertise and resources to meet the specific needs of the French healthcare system, ensuring the availability of high-quality generic medications in critical therapeutic categories.

2Sourcing Profile

Zydus France's sourcing strategy emphasizes the importation of generic drugs, particularly in the antiviral and HIV medication categories. The company's preference for finished pharmaceutical formulations over raw active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market products that can be directly distributed within the French market. India's established reputation for producing high-quality generic medications positions it as a key supplier for Zydus France, aligning with the company's objectives to provide affordable and effective treatments to the French population.

Frequently Asked Questions — Zydus France

What products does Zydus France import from India?

Zydus France imports 2 pharmaceutical products across 1 categories. Top imports: Emtricitabine ($600.0K), Tenofovir ($500.0K).

Who supplies pharmaceuticals to Zydus France from India?

Zydus France sources from 4 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (68.6% of imports, $650.0K).

What is Zydus France's total pharmaceutical import value?

Zydus France's total pharmaceutical import value from India is $1.1M, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Zydus France focus on?

Zydus France imports across 1 categories. The largest: Antiviral & HIV Medications (100.0%).

Get Full Zydus France Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Zydus France

Zydus France — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Zydus France?

What Formulations Does Zydus France Import?

What Products Does Zydus France Import?

Top Products by Import Value

Zydus France Therapeutic Categories — 1 Specializations